Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

Launched by ASTRAZENECA · Jul 2, 2024

Keywords

ClinConnect Summary

The Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study is a clinical trial designed to learn more about how doctors are testing and treating patients with advanced non-small cell lung cancer (NSCLC). This study specifically looks at patients who have recently been diagnosed with metastatic NSCLC, which means that the cancer has spread beyond the lungs. The goal is to understand the patterns of molecular testing and treatment options available to these patients after implementing quality improvement strategies.

To participate in this study, individuals need to be at least 18 years old and have a recent diagnosis of metastatic NSCLC (stage IV). Participants should also be in generally good health, as indicated by a performance status of 0-2, meaning they can carry out daily activities with little to no issues. Throughout the study, participants can expect to contribute to important research that may improve lung cancer care, but they will not be able to join if they are enrolled in other clinical trials or if their doctor believes they may not be able to follow the study's requirements. This study is currently open for recruitment, welcoming all eligible patients who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years, at the time of signing the informed consent.
• • ECOG performance status 0-2.
• • Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.
• Exclusion Criteria:
• • Be participating in other intervention clinical trials.
• • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
• • Previous enrolment in the other QIP study.